#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Semaglutide vs SGLT2 inhibitors in MASLD
A propensity-matched TriNetX study compares semaglutide against SGLT2 inhibitors in patients with fatty liver disease and type-2 diabetes.
Weight-loss drugs and fertility: the data
A meta-analysis of seven trials finds orlistat and semaglutide may boost ovulation and pregnancy rates in women with obesity.
ACP review: which obesity drugs pay off?
A new ACP systematic review rates tirzepatide high-value but flags poor study quality across all obesity drug cost models.
ACP: tirzepatide, semaglutide first-line
A living ACP guideline published 16 June 2026 places tirzepatide and semaglutide first among pharmacologic obesity treatments for US outpatient adults.
GLP-1 drugs and plastic surgery risks
A 2026 review examines wound risks, aspiration concerns and body-contouring challenges when aesthetic surgery patients use GLP-1 agonists.
Medicare's $50 GLP-1 bridge may never end
A temporary Medicare program offers GLP-1 weight-loss drugs for $50 a month from July 2026. It has already been extended once.
Semaglutide and pancreatic cancer risk
A 2026 meta-analysis of randomised trials found no increased pancreatic cancer risk with semaglutide, consistent with two earlier reviews of the GLP-1 class.
Semaglutide QoL gains: real but modest
A 2026 meta-analysis finds semaglutide 2.4 mg improves physical functioning scores, but gains fall below clinically meaningful thresholds.
Semaglutide vs dulaglutide in UK practice
A UK cohort study of 6,616 adults found semaglutide lowered HbA1c by 0.22 points more than dulaglutide over one year, with 1.92 kg more weight loss.
Boerhaave syndrome after semaglutide use
A 2026 case report describes the first documented esophageal perforation linked to GLP-1 agonist-induced vomiting after skipping dose titration.
Switching Peptides: What the Evidence Says
No clinical guideline covers switching between incretin-class peptides. Prescribing information and early research both say: start at the lowest dose.
Which drugs flag for gastric motility risks
A 2026 study screened 58 million adverse-event reports. Semaglutide had the strongest signal for impaired gastric emptying.